3RB1 Stock Chart & Stats
€11.60
-€0.10(-0.85%)
At close: 4:00 PM EDT
€11.60
-€0.10(-0.85%)
Day’s Range― - ―
52-Week Range€10.30 - €14.06
Previous CloseN/A
Volume0.00
Average Volume (3M)7.00
Market Cap
€38.11B
Enterprise Value€54.62K
Total Cash (Recent Filing)€872.70M
Total Debt (Recent Filing)€10.10B
Price to Earnings (P/E)11.6
Beta0.30
Next Earnings
Mar 03, 2027EPS Estimate
0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.88
Shares Outstanding3,174,305,400
10 Day Avg. Volume0
30 Day Avg. Volume7
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)5.08
Price to Sales (P/S)2.83
P/FCF Ratio22.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€12.35Price Target Upside6.49% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)0.77
Revenue Forecast (FY)€14.97B
Bulls Say, Bears Say
Bulls Say
Branded Consumer Health And Hygiene PortfolioReckitt’s portfolio spans consumer health, hygiene and nutrition, with established brands, repeat-purchase demand and broad retail and e-commerce distribution. This diversification supports customer reach and can provide resilience across categories and geographies.
Emerging-Market Growth And InnovationStrong emerging-market growth and sustained Chinese momentum provide a durable expansion avenue, while successful launches such as Dettol Activ Botany and Durex Intensity can extend brands, improve mix and support market-share gains.
Cost Program And Margin ResilienceDespite input-cost pressure, margin remained ahead of expectations and fixed costs were broadly controlled. The multiyear Fuel for Growth program offers a structural route to efficiency, helping protect profitability as revenue growth improves.
Bears Say
Weak Top-Line Momentum In Developed MarketsRecent revenue contraction indicates that cost savings are compensating for weak underlying demand in important businesses. Household Care and developed markets remain pressured, creating execution risk if innovation and recovery plans do not restore volume growth.
Meaningful Leverage And Declining Cash FlowLeverage reduces financial flexibility, while the recent decline in operating and free cash flow makes deleveraging and shareholder distributions more dependent on a sustained earnings recovery. Softer profits could increase refinancing and capital-allocation pressure.
Infant Formula Litigation ExposureThe litigation creates potentially material legal, financial and reputational exposure in the Mead Johnson nutrition business. A large case inventory and an active bellwether trial could prolong uncertainty and affect future cash deployment or operating focus.
3RB1 FAQ
What was Reckitt Benckiser Group’s price range in the past 12 months?
Reckitt Benckiser Group lowest stock price was €10.30 and its highest was €14.06 in the past 12 months.
What is Reckitt Benckiser Group’s market cap?
Reckitt Benckiser Group’s market cap is €38.11B.
When is Reckitt Benckiser Group’s upcoming earnings report date?
Reckitt Benckiser Group’s upcoming earnings report date is Mar 03, 2027 which is in 187 days.
How were Reckitt Benckiser Group’s earnings last quarter?
Reckitt Benckiser Group released its earnings results on Jul 29, 2026. The company reported €0.231 earnings per share for the quarter, missing the consensus estimate of €0.326 by -€0.096.
Is Reckitt Benckiser Group overvalued?
According to Wall Street analysts Reckitt Benckiser Group’s price is currently Undervalued.
Does Reckitt Benckiser Group pay dividends?
Reckitt Benckiser Group does not currently pay dividends.
What is Reckitt Benckiser Group’s EPS estimate?
Reckitt Benckiser Group’s EPS estimate is 0.44.
How many shares outstanding does Reckitt Benckiser Group have?
Reckitt Benckiser Group has 3,174,305,400 shares outstanding.
What happened to Reckitt Benckiser Group’s price movement after its last earnings report?
Reckitt Benckiser Group reported an EPS of €0.231 in its last earnings report, missing expectations of €0.326. Following the earnings report the stock price went up 4.309%.
Which hedge fund is a major shareholder of Reckitt Benckiser Group?
Currently, no hedge funds are holding shares in DE:3RB1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Reckitt Benckiser Group Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€12.35 (6.49% Upside)
€12.35 (6.49% Upside)
Blogger Sentiment
Bullish
DE:3RB1 Sentiment 75%
Sector Average 56%
Sector Average 56%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.45%
12-Months-Change
Fundamentals
Return on Equity
8.66%
Trailing 12-Months
Asset Growth
-3.90%
Trailing 12-Months
Company Description
Reckitt Benckiser Group
Reckitt Benckiser Group Plc engages in the manufacture and trade of consumer brand products including Air Wick, Calgon, Cillit Bang, Clearasil, Dettol, Durex, Enfamil, Finish, Gaviscon, Harpic, Lysol, Mortein, Mucinex, Nurofen, Nutramigen, Strepsils, Vanish, Veet, and Woolite. It operates through the following segments: Hygiene, Health, and Nutrition. The company was founded by Isaac Reckitt in 1840 and is headquartered in Slough, the United Kingdom.
3RB1 Company Deck
3RB1 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a constructive tone driven by clear Q2 acceleration, strong emerging market execution and successful innovation launches, supported by disciplined cost actions under the Fuel for Growth program and active shareholder returns. Material lowlights remain: the dilutive impact of the Essential Home divestment (pressuring EPS and operating profit), gross margin headwinds from higher input costs and commodity volatility, weakness in Household Care/Auto Dish and some developed-market softness. Management reiterated guidance and emphasized confidence in mitigation plans, leaving the narrative net positive but balanced by identifiable execution and macro risks.View all DE:3RB1 earnings summaries3RB1 Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
€12.35
▲(6.49% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month








